Aligos Therapeutics (ALGS) Other Working Capital Changes (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Other Working Capital Changes came in at -$671000.0 in Q3 2024, up 38.04% YoY from -$486082.3 in Q4 2023, and down 210.91% on a QoQ basis from $605000.0 in Q2 2024.
Aligos Therapeutics (ALGS) Other Working Capital Changes (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 4 years of Other Working Capital Changes data on file, last reported at -$671000.0 in Q3 2024.
- Quarterly Other Working Capital Changes rose 38.04% year-over-year to -$671000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was -$1.2 million (down 133.82% YoY) and the FY2023 annual result came in at $524000.0, changed N/A from the prior year.
- Other Working Capital Changes fell to -$671000.0 in Q3 2024, from $605000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $4.3 million in Q3 2022 to a low of -$5.5 million in Q2 2022.
- A 5-year average of -$559823.5 and a median of -$318000.0 in 2026 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 1466.81% in 2022, down 167.08% in 2022.
- Tracing ALGS's Other Working Capital Changes over 4 years: stood at -$367000.0 in 2021, then tumbled by 1018.53% to -$4.1 million in 2022, then jumped by 84.56% to -$634000.0 in 2023, then dropped by 5.84% to -$671000.0 in 2024.
- The last three Other Working Capital Changes figures came in at -$671000.0 (Q3 2024), $605000.0 (Q2 2024), and -$503000.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aligos Therapeutics | 68.90 Mn | 38.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -831,000.00 |
| Jun 30, 2026 | -831,000.00 |
| Jun 30, 2026 | -831,000.00 |
| Mar 31, 2026 | -318,000.00 |
| Mar 31, 2026 | -318,000.00 |
| Mar 31, 2026 | -318,000.00 |
| Dec 31, 2025 | 626,000.00 |
| Dec 31, 2025 | 626,000.00 |
| Dec 31, 2025 | 626,000.00 |
| Sep 30, 2025 | 722,000.00 |
| Sep 30, 2025 | 722,000.00 |
| Sep 30, 2025 | 722,000.00 |
| Jun 30, 2025 | -1.35 Mn |
| Jun 30, 2025 | -1.35 Mn |
| Jun 30, 2025 | -1.35 Mn |
| Mar 31, 2025 | -151,000.00 |
| Mar 31, 2025 | -151,000.00 |
| Mar 31, 2025 | -151,000.00 |
| Dec 31, 2024 | 809,000.00 |
| Dec 31, 2024 | 809,000.00 |